315 related articles for article (PubMed ID: 16707008)
1. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma.
Koch CA; Brouwers FM; Vortmeyer AO; Tannapfel A; Libutti SK; Zhuang Z; Pacak K; Neumann HP; Paschke R
BMC Cancer; 2006 May; 6():131. PubMed ID: 16707008
[TBL] [Abstract][Full Text] [Related]
2. Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma.
Koch CA; Huang SC; Zhuang Z; Stolle C; Azumi N; Chrousos GP; Vortmeyer AO; Pacak K
Oncogene; 2002 Jan; 21(3):479-82. PubMed ID: 11821960
[TBL] [Abstract][Full Text] [Related]
3. Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma.
Koch CA; Huang SC; Moley JF; Azumi N; Chrousos GP; Gagel RF; Zhuang Z; Pacak K; Vortmeyer AO
Oncogene; 2001 Nov; 20(53):7809-11. PubMed ID: 11753660
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
5. Genetics of medullary thyroid cancer: An overview.
Accardo G; Conzo G; Esposito D; Gambardella C; Mazzella M; Castaldo F; Di Donna C; Polistena A; Avenia N; Colantuoni V; Giugliano D; Pasquali D
Int J Surg; 2017 May; 41 Suppl 1():S2-S6. PubMed ID: 28506408
[TBL] [Abstract][Full Text] [Related]
6. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II.
Neumann HP; Eng C; Mulligan LM; Glavac D; Zäuner I; Ponder BA; Crossey PA; Maher ER; Brauch H
JAMA; 1995 Oct; 274(14):1149-51. PubMed ID: 7563486
[TBL] [Abstract][Full Text] [Related]
7. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
[TBL] [Abstract][Full Text] [Related]
8. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
[TBL] [Abstract][Full Text] [Related]
9. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.
Marsh DJ; Andrew SD; Eng C; Learoyd DL; Capes AG; Pojer R; Richardson AL; Houghton C; Mulligan LM; Ponder BA; Robinson BG
Cancer Res; 1996 Mar; 56(6):1241-3. PubMed ID: 8640806
[TBL] [Abstract][Full Text] [Related]
10. Coincidence of multiple endocrine neoplasia type 2A with acromegaly.
Saito T; Miura D; Taguchi M; Takeshita A; Miyakawa M; Takeuchi Y
Am J Med Sci; 2010 Oct; 340(4):329-31. PubMed ID: 20739875
[TBL] [Abstract][Full Text] [Related]
11. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
[TBL] [Abstract][Full Text] [Related]
12. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
13. Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes.
Ercolino T; Lai R; Giachè V; Melchionda S; Carella M; Delitala A; Mannelli M; Fanciulli G
Gene; 2014 Feb; 536(2):332-5. PubMed ID: 24361808
[TBL] [Abstract][Full Text] [Related]
14. Modifying impact of
Kaczmarek-Ryś M; Ziemnicka K; Pławski A; Budny B; Michalak M; Hryhorowicz S; Hoppe-Gołębiewska J; Boruń P; Gołąb M; Czetwertyńska M; Sromek M; Szalata M; Ruchała M; Słomski R
Endocr Relat Cancer; 2018 Apr; 25(4):421-436. PubMed ID: 29386230
[TBL] [Abstract][Full Text] [Related]
15. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
Moore SW; Appfelstaedt J; Zaahl MG
J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
[TBL] [Abstract][Full Text] [Related]
16. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Krampitz GW; Norton JA
Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
[TBL] [Abstract][Full Text] [Related]
17. No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma.
Bockhorn M; Frilling A; Kalinin V; Schröder S; Broelsch CE
Langenbecks Arch Surg; 1999 Feb; 384(1):60-4. PubMed ID: 10367632
[TBL] [Abstract][Full Text] [Related]
18. The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes.
Zupan A; Glavač D
Exp Mol Pathol; 2015 Dec; 99(3):416-25. PubMed ID: 26321248
[TBL] [Abstract][Full Text] [Related]
19. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
Menon MM; Simha MR
Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
[TBL] [Abstract][Full Text] [Related]
20. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
